Stockreport

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc.  (IMNM) 
PDF IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected [Read more]